ALS has delivered a sharp lift in underlying earnings and dividend growth, powered by a 30.4% organic surge in Minerals. But the result also exposes a weaker side of the portfolio, with Life Sciences growth expectations cut to about 3% for FY27.
ALS Limited reported a 25.8% jump in underlying net profit after tax to AUD 381.2 million for FY26, driven by strong commodity testing demand and margin expansion. The company raised its dividend and advanced major hub lab projects while navigating a post-year-end cyber incident.